Hemostasis and Thrombosis Program
In collaboration with Emory University, we follow more than 1,000 children and adults with bleeding disorders and approximately 200 with clotting disorders in our Comprehensive Hemostasis and Thrombosis Program. We treat a wide range of disorders, including hemophilia, thrombosis and von Willebrand disease.
Our program:
- Is a recognized leader among treatment facilities in the U.S. for achievements in care, education and research for patients with congenital bleeding disorders.
- Has developed a successful, integrated pediatric- and adult-care model that reduces the stress and barriers associated with transitions from a pediatric to an adult-care facility for patients with bleeding disorders.
- Participates in innovative clinical, epidemiological, translational and basic science research designed to provide leading-edge therapies and eventual cures.
- Was recently awarded a grant to be the national private for ATHN 9 American Thrombosis and Hemostasis Network Study entitled “A Real-World Safety and Efficacy Study of Prophylaxis for Severe von Willebrand Disease.”
- Is completing an NHLBI U54 award entitled “Translational Research Centers in Thrombotic and Hemostatic Disorders,” and was recently selected as one of four NHLBI-funded Centers for the Investigation of Factor VIII Immunogenicity.
- Team investigators were selected as one of three national NHLBI U54 Centers for the Investigation of the Factor VIII Immune Response in Patients with Hemophilia A. The U54 grant is a five-year award that will expire in 2023.
Click the button for more information about our program and research.